to Thanks, Elizabeth. our welcome Good afternoon, earnings everyone, XXXX and call. quarter first
constant Pulmonx Joshi, $XX.X XXXX, same me growth Chief in delivered deliver with the to $XX previously Financial sales year, see Officer.
I of on full XXXX. currency XX% this to our first worldwide our is year million in quarter basis. to in leaves million a our excited and confident last on in report year strong increasingly guidance over Here Mehul momentum us ability am of which period such the to million revenue communicated $XX We're that early pleased the XX% representing for
to strategy a team's sharing drive I our progress. sustainable with long-term Our and reflect continued forward success results today our on growth, comprehensive look executing QX updates you key in to
our performance detailing Pulmonx. some Before changes leadership to speak at I'd of the priorities, about recent and key like
maintains the innumerable congratulate contributions for serving through and French him his space to his pulmonology and thank while Glen broadly, the like on long as more and I'd First, the retirement his interventional as closely to in company, tenure ensure our I few smooth have last and our continued Board months of his look an worked collaboration and the he I Glen over Directors. on position forward to exceptionally CEO. transition, our to
brings industry leverage. I'm like for a have veteran delighted financial of to its take working Controller. and I executive finance CFO, for continued and growth. and be an Mehul team. look Board hired phase ResMed, leadership our thank knowledge Gilead as I'm revenue Corporate companies, I'd scale a thrilled high-growth alongside as as Interim next they as opportunity CFO to to welcome VP to I'd as and team high operating of such priority to John like the role. forward myself, and Appointing teams leading Second, depth to drive to also him our our contributions Mehul our experienced McKune accomplished was to and serving Pulmonx for and into broader his Joshi our within global the an
through product with phase. leading excited teams transformational the Pulmonx care adoption. at across market the Before quarter, bit nearly focused More markets well I'd technologies. helped that rapid and development discuss of CR be large specifically, Across next developing I'm of a to as led details Bard diversified as large Becton, my a to new spent strong of businesses understanding needs, growth global have revolutionize role, I driving I've on companies share I've why teams at cross-functional like Outset so we this as leading high-growth and cadence and decades Hologic, background each Dickinson customer such X patient Medical.
success. developed checks I've technology Pulmonx in Through my I first, boxes. a learned as its affirmed large the and serve a demonstrated proposition; foundation three that company company of second, last collectively for diligence population As CEO, needs; a each with third, the my the I the what X.X these months value evaluated patient solution economic focused opportunity, significant long-term diligence, and is with a has does Pulmonx I pillars: clinical highly impactful, on unmet three transformative
approximately treatment resulting billion. we First, on from limited not up potential X.X which estimate total globally. represents large More the million in our a Zephyr account with addressable focused opportunity and with market patients to population Pulmonx is to for opportunity incremental the emphysema associated our $XX XX% does Valve approximately by the market of expand we This today underserved market has benefit to AeriSeal, expect a with patient stand treatment severe global addressable that options. specifically,
long-term reduction lung obvious transplantation, the new in doing efficacy, experience and me surgery or such with as as as deconditioning, live significant that treatment technologies, robs that management treatments breathlessness Patients increases limited gap This their show as both activity. spiral Valves. pulmonary standard face them with care of severe progressive Many ability with their the expanding volume of spectrum and medical chronic rehabilitation, activities risk just both lung with and and resonates well altering developing risks. which of life Zephyr transformative which on a markets a do mortality. highly we're basic present the options of Current which of disease emphysema day-to-day given include my to invasive morbidity with them downward significantly puts limits mortality while treatment
trials guidelines, be and basis and I invasive over treated will articles. show benefits clinically am that key have function, broad Valve medical undergoing because improvements X which exercise we minimally in significant by durable compared that statistically treatment confident demonstrate data, payer coverage Zephyr These for patients inclusion with quality management Valve have scientific randomized of experienced and Zephyr life capacity lung in to validated clinical the successful treatment served validated by as patients meaningful and significant been alone. outcomes XXX and as real-world with
growth so impactful because successful In just financially clear because summary, the operationally and for I many Pulmonx me the is can patients I at strategy. be is to it this execute Zephyr long-term and well view how a company took Valve treatment opportunity positioned to
I expertise unparalleled. interventional for our collective mission to treatments on experience team minimally ahead, global pulmonology excited invasive as the dedication our leverage As of to is the COPD and to entire our look deliver whose I'm in commitments in leader
team's back key pivot to on like I'd quarter my to said, for that priorities performance, XXXX. perspectives early With and our strategy our first our
earlier, year a worldwide the currency mentioned and XX% XX% same on delivered sales constant I basis. As of million last $XX.X representing Pulmonx in XXXX, first period the over growth in quarter
was on the our has United fueled As in success primarily growth strategy. States the executing expected, laser-focused the team been by where commercial
training has Valve the that team among been at sharing hospitals areas: be and high-performing second, optimize three patients. centers; in best Zephyr our centers third, focused of to benefits of facilitating their among first, and potential building treatment existing practices physicians local of to awareness the the Zephyr our have programs; Valve COPD Specifically, physicians
Based growth to confident our on recent strategy. field my success, in early I sustainable three-pronged our ability in this the and experiences with drive am increasingly
coming closely the with team we in design I more place. in have the look months, the specific providing serve detail perspectives work weeks recent will that intend to I and building near to blocks strategies forward to to Over the these future. on optimize
on of accounts, having Regarding new and new establish driving high-performing expect XXX our in first expectations. We'll number new placed we centers, continue with a the in U.S. Of accounts bringing which focus Valve in is in the X active quarter to XXXX, a first total our to Zephyr the revenue-generating our with opportunistically to centers these, active Valve order were accounts. quarter, utilization Zephyr XXX. identify in potentially centers line added
to hospitals to whose our valve Valve utilization routinely staff centers. for prospective to procedures well Zephyr help screen treatment our identify results valve Valve instituting ease continues investing routine dedicated best a We're The may increasing in of indicate higher team as sharing procedure, up test the of Zephyr seeing particularly as through candidates candidates. patients as treatment they an practices number of establish more
year-over-year these centers improvement piloting will patients. programs annualized patient that to improved benefiting on efforts we're patient and year-over-year cases treatment, continue for from experience optimize an per in and capacity to in the to led more Additionally, moving average to of time to active resulting have expect workflow, we forward. customers Collectively, center, basis sustained reduced enable greater gains number evaluate
and our Valve treatment, to aim benefits geographies efforts education patients well-developed on cost-efficient our already of and particularly availability programs. the providers Lastly, in inform Zephyr with
based also a and prospective who early patients field-based about engage learn search focusing and supporting rapidly geofencing treatment identify Zephyr more to continue educate enhancing seeking have high-volume to and traction. digital We're several to identify Zephyr are more physicians benefit from education additional and launched programs, trends. which tactics have on who may COPD garnered Valves find our on treatment while center patients We
by across have strategies is reduced accounts. geographies, in more cohort the thereby in improved engagement select even early there to driving right of that has playbook and ongoing programs costs pilot our and recent top that reinforced confidence these Our in over even quarters we success within demonstrating been grow acquisition room
place within continue ahead, campaigns. awareness that we'll and deploy pieces on a tactics before heavily given are investing success look to in resources basis, local an in account-by-account geography ensuring strategically more critical we As
business, see substantial primary X to been In Europe, last on making growing and field our to remains course quarters, the of commercial team the enhancements continue internationally. over opportunity our our While focus substantial U.S. growth we management capabilities. we've
been such markets, engagement as use European use the operational U.S. adapting and peer-to-peer we've in practice education programs. we've and many tools community for addition, the sales In best developed physician in for of taking sharing, them
we saw and geographies as a impact foundation changes, these by our focus XX% France, our QX of in in our international XX% in as year. As increasingly year-over-year efforts anticipate Spain. the Germany, business U.K. result and a building this on international evident to grow become whole top of we We XXXX of
announce the post-approval Respiratory to our patient the to among study. United addition interest I post-market the commercial join our encouraged In our at study. centers the excited positive treatment Japanese and am Japanese of approval of in States, reception We're recent by Society efforts meeting outside the growing in technology to the the first
and we As it of through of and back train to the enrollment option, as awareness the bulk a funnel. sites treatment to enrollment period expect anticipate we time the treatment grow new the the additional half take we first in patients reminder, occur of move will this
a a do we towards where until were from study we market Japan an not new stand material patients when Zephyr This broader broadly. Valves. to essential revenue contribution more marks approximately able step XXXX expect estimate and from commercialize approximately to XXX,XXX commercialization We benefit
COPD/emphysema be to Valves severe the Zephyr the have of trial expect our the number XXX-patient approval a next AeriSeal CONVERT the evaluating following receipt safety limiting our can the patients effectiveness FDA. for treated We treatment We of ventilation that also progress from to announced pivotal IDE continued goal toward In in of February, II patient the make in global of trial, of study end multicenter of with expanding we the the patients. collateral and approximately currently enroll through year. system in first
evaluated care who standard per at rate, CV-negative following volume experienced lung treatment rate to reduction. be Valves and reduction of be success placement will volume will success conversion clinical parameters lung implanted other Zephyr used post-valve be AeriSeal status and PMA Patients support our months current Conversion application. with for to then X will
We last also the I to enrollment of our data completion following year. look forward presentation study CONVERT final from
Respiratory European We in data presented at expect the be Congress Society to Vienna. in these early September
campaigns by with with in program. XXXX AeriSeal excited encouraged our conclusion, our the we've pleased In outlook the performance, growth market and are development we our progress QX development made for clinical and
has significant confidence the In already the growth realized I've experience our treatment, my on market in by leadership achieve accelerate been with my benefits place. team to initial Zephyr execute for forward commercial time our to receiving and opportunities look foundation opportunity to to the I with patients validated Pulmonx, our identify to profitability. in Valves continue strategy, the working and
Now the call our results. of to Mehul more review I'll quarter turn to a provide over first detailed
